11 results about "Fusobacterium nucleatum" patented technology

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The application discloses application of an ABC transporter substrate-binding protein in preparation of an anti-Fusobacterium nucleatum vaccine and belongs to the technical field of biotechnology.The ABC transporter substrate-binding protein (ABC-sbp) is a rnlrABC-sbp without a leading region which is expressed by an E. coli expression system, and the amino acid sequence of the rnlrABC-sbp is shown as SEQ ID NO. 2. In addition, the application further discloses a genetic engineering subunit vaccine against the Fusobacterium nucleatum, which comprises the rnlrABC-sbp protein with the amino acid sequence shown as SEQ ID NO. 2 and an adjuvant. The genetic engineering subunit vaccine against the Fusobacterium nucleatum prepared by using the rnlrABC-sbp protein can stimulate the body to produce a large amount of antibodies, resist the attack of the Fusobacterium nucleatum, reduce the damage of the body and improve the survival rate, and has important application value in the field of prevention and treatment of the Fusobacterium nucleatum infection.

The application relates to the application of natural plant extracts in the field of oral health, and particularly discloses the application of an extract of Ilex hainanensis Merr in oral health care products. The Ilex hainanensis Merr dichloromethane extract is eluted by high-concentration ethanol through a macroporous resin, and is rich in dihydrochalcone active ingredients, has significant inhibitory activity on Porphyromonas gingivalis and Fusobacterium nucleatum, and has no inhibitory effect on Streptococcus mutans, can selectively inhibit periodontal pathogenic bacteria without destroying the oral microecological balance, and is suitable for preparing toothpaste, mouthwash, oral spray and other oral health care products.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

This invention belongs to the interdisciplinary field of natural product medicinal chemistry and oral medicine, specifically disclosing the application of uvangoletin in the preparation of anti-periodontalgia drugs. Uvangoletin is 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-1-propanone, with the molecular formula C. 16 H 16 O4, experiments confirmed that its MIC for Porphyromonas gingivalis was 16 μmol / L, MIC 50 The concentration is 10.28 μmol / L, the MIC for Fusobacterium nucleatum is 16 μmol / L and the MIC50 is 6.86 μmol / L. It has no inhibitory activity against Streptococcus mutans and has selective anti-periodontal pathogenic bacteria characteristics. It can be made into oral preparations such as gels, mouthwashes or toothpaste.

The present invention relates to a novel peptide comprising the amino acid sequence of SEQ ID NO: 1, and an antibacterial composition comprising same. The peptide of the present invention, which is an Enterococcus lactis-derived antibacterial peptide APP101, has specific antibacterial activity against periodontitis-causing bacteria including Porphyromonas gingivalis, Fusobacterium nucleatum, Enterococcus faecalis, Streptococcus parasanguinis, and Streptococcus salivarius, and has stability against proteases, pH, and salt concentrations. The antimicrobial composition of the present invention can be usefully employed for the prevention or treatment of periodontitis.

The application discloses preparation and application of anti-Fusobacterium nucleatum PknK and PknL protein monoclonal antibodies and belongs to the technical field of biotechnology. The application takes two virulence proteins PknK and PknL of the Fusobacterium nucleatum as immunogens, successfully prepares monoclonal antibodies against the serine / threonine protein kinases PknK and PknL of the Fusobacterium nucleatum through hybridoma cell fusion technology, and the two monoclonal antibodies against the PknK and PknL proteins of the Fusobacterium nucleatum have good safety, thereby providing a basis for clinical drug safety. More importantly, the antibodies can not only efficiently neutralize bacterial toxins and directly eliminate the pathogenicity of the Fusobacterium nucleatum, but also can be directly combined on the bacterial surface to enhance the recognition and phagocytosis efficiency of immune cells to the bacteria, thereby clearing pathogenic bacteria, and is expected to be developed into a drug for resisting the Fusobacterium nucleatum infection and has a very good application prospect.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

This invention discloses a dihydrochalcone-based oral spray and its preparation method, belonging to the field of oral pharmaceutical formulations. The spray uses 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-1-propanone and 2',6'-dihydroxy-3',4'-dimethoxydihydrochalcone, isolated and purified from *Sarcandra glabra*, as active ingredients. It is solubilized using a medium-chain triglyceride / polyoxyethylene hydrogenated castor oil / propylene glycol self-microemulsification delivery system, and hydroxypropyl methylcellulose is introduced to enhance mucosal adhesion. This spray can spontaneously form nanoemulsion droplets in oral saliva, selectively inhibiting *Porphyromonas gingivalis* and *Fusobacterium nucleatum*, and is suitable for adjunctive treatment of gingivitis and periodontitis.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.